| INTRODUCTION
Fragile X syndrome (FXS) remains the most common inherited cause of intellectual disability (ID) and autism spectrum disorder (ASD). It is the result of CGG expansion mutation of greater than 200 repeats on the Fragile X Mental Retardation 1 gene (FMR1) at Xq27.3. This expansion leads to hypermethylation and transcriptional silencing of the gene and consequently the reduction in the gene's product, FMR1 protein (FMRP). FMRP is important for neurologic function and cognitive development; hence, its absence results in varying levels of ID. 1, 2 Comorbid conditions common in FXS include behavioral problems such as ADHD, anxiety, ASD, self-injurious behaviors and aggression. 3, 4 Medical comorbidities include recurrent otitis media, gastrointestinal reflux, seizures, strabismus, sleep problems, obesity and growth disorders. 1, 5 Growth findings suggest that patients with FXS have a higher risk for being overweight and diminished height in adulthood. 1, 6 Obesity is a common problem seen in FXS. Male children less than 20 years old had a higher prevalence rate of obesity (31%) when compared to matched control children (18%). 6 The behavioral phenotype of FXS can include overfilling the mouth and overeating leading to an excess caloric intake compared to energy expenditure. 7 The Prader-Willi phenotype (PWP) of FXS 8 describes a subgroup of patients that develop severe hyperphagia, obesity, hypogonadism or delayed puberty. Unlike Prader-Willi syndrome (PWS), this phenotype does not have a deletion of 15q11-q13 or maternal uniparental disomy. 2, 6 Studies have shown that FMRP binds to cytoplasmic Metformin decreases protein synthesis and insulin signaling (IS) via the AMPK/Akt/mTOR pathway, it also inhibits the lipid and sterol biosynthetic pathways. 22 Looking at the potential signaling pathways, metformin in FXS may decrease insulin signaling and restore the circadian output pathway and in turn have positive effects on memory and sleep. 2 
| MATERIALS AND METHODS
Here we report several cases of patients with FXS that have been treated clinically with metformin. All patients have signed an informed consent for developmental and molecular testing approved by the institutional IRB and all families have consented to have their clinical response to metformin published.
Cases were seen as part of the Fragile X Treatment and Research
Center at the MIND Institute UCDMC for management of FXS. Each case is described with their corresponding medical and behavioral comorbidities in addition to laboratory studies pre and post treatment.
Patients have been treated for at least 6 months. These cases represent the first cases treated with metformin in whom a behavioral questionnaire and laboratory studies were obtained. All but case 7 were prescribed metformin for obesity or type 2 diabetes management and were additionally observed for behavior and metabolic improvements.
3 | RESULTS
| Case 1-Overweight with impaired glucose tolerance
A 19-year-old male diagnosed with FXS and ASD at age 5 has an ongoing history of hyperphagia and lack of satiety after meals. He has not been known to hoard food nor was it necessary to lock cupboards. He is easily redirected and follows behavioral plans for meal times. He also exhibits behavioral issues of aggression with adolescence, severe skin picking and scratching, hand biting, poor eye contact, tactile defensiveness, hyperactivity, perseveration and ADHD.
He has been prescribed several medications to treat these symptoms in the past including methylphenidate, amphetamine, lamotrigine, risperidone, divalproex sodium, sertraline, atomoxetine, ziprasidone, quetiapine, fluvoxamine and minocycline. At present, he is on minocycline 200 mg qd, divalproex sodium 1000 mg tid, guanfacine 2 mg bid, and fluvoxamine ER 100 mg qd. As he has gotten older, aggression of adolescence has decreased, although over the last few weeks he had become more agitated and aggressive. He continues to have hyperphagia and lacks satiation after meals. 
| Case 2-FXS/PWP
Case 2 is a 13-year-old boy with FXS who was first seen at age 5 after his diagnosis of FXS demonstrating a full mutation. His mother His behavior improved but intermittent aggression persisted and at age 12 he was started on metformin beginning at 500 mg at dinnertime and subsequently increased to bid. His examination at age 12 demonstrated a small penis buried in his fat and testicles at 10 mL bilaterally. His face was round and obese with striae across his abdomen and prominent cupped ears. He met criteria for the PWP of FXS.
Metformin has been very helpful for him over the last year according to his mother and his care center. Although he initially had loose stools they subsequently normalized after a month and he had tolerated the 500 mg bid without side effects. He is calmer and patient, more responsive to rewards and able to work longer with less agitation and less aggression. He follows directions far better. He has more understanding when things are explained to him and he negotiates more with teachers. In the past before the metformin he was constantly asking for food and now he does not.
| Case 3-FXS/PWP
A 19-year-old boy diagnosed with FXS, ADHD, specific phobias and ASD. He was diagnosed with FXS at 3 years. He has episodes of behavioral outbursts that are described as impulsive and not aggressive. He has a history of persistent hyperphagia exhibited by constantly asking for food and preferring high caloric food items, and avoiding exercise. He had delayed puberty which did not begin until he was 17 years old and morbid obesity seen with a BMI of 44 kg/ m 2 . In addition, he has also developed hypertension and low vitamin D level.
On physical examination, his blood pressure was 142/87, Tanner stage IV. Behavioral concerns include enuresis, binge eating causing him to vomit almost every day, and skin picking. His medications include minocycline 100 mg qd, sertraline 50 mg qd and aripiprazole 2.5 mg qd. Because of his morbid obesity this boy was started on metformin 500 mg bid. He has been advised to have nutrition counsel regarding meals. He experienced diarrhea in the mornings after his AM dose so the family lowered his dose to 500 mg at dinner which was well tolerated. After 6 months of treatment his weight did not change from baseline of 299 lbs. His appetite was slightly lowered but he experienced significant improvements in behavior including cessation of his head-banging and other self-injurious behavior, decrease in tantrums and improvement in his communication ability. His dose was increased to 750 mg at dinner and if tolerated will increase to 1000 mg after 2 weeks. See Tables 1 and 2 for improvements in ABC and laboratory measures.
| Case 4-Overweight
A 60-year-old female adult diagnosed with FXS and mild ID, who has been seen regularly since he was 51 years. She is currently in a group home and undergoes a daily living skills development program. She has a history of morbid obesity and had undergone gastric bypass when she was 45 years old with minimal improvement in her obesity.
There are concerns for her overeating, favoring and enjoying snacks and peanut butter. She has not been known to hoard food, and is mostly compliant when placed on diet restrictions. At moments that she does overeat, she presents with a bulimic-like picture and would induce vomiting. She also shows repetitive behavior and her caregivers have concerns for her memory deficits, agitation and anxiety.
Other medical concerns include hypertension and gastric esophageal She was started on metformin 500 mg at dinner and then increased to bid after a week. She has not had side effects and her eating habits have changed such that she is not over-eating and she is not snacking between meals. After 8 months of treatment with metformin she has lost 19 kg (41.3 lbs) and has improved her irritability and social responsiveness (see Tables 1 and 2 ).
| Case 5-Overweight
Case 5 is a 31-year-old man with FXS who has been followed at the MIND since age 16 when he was also diagnosed with ASD and his full scale IQ was 54 on the WISC III. He has had problems with anxiety and tantrums and he was treated with citalopram 20 mg, which was helpful for his anxiety and subsequently aripiprazole which was helpful for his aggressive behavior and intermittent tics. However, he gradually gained weight so the aripiprazole was tapered and discontinued at age 29. His father passed away at age 28 and he experienced significant grief but he had difficulty in verbalizing his sadness.
He was seen at age 30 and he was obese with a weight of 110.5 kg (243 lbs) and BMI of 30.7 kg/m 2 . His glucose was 104 and his HgbA1c was 5.1. His examination was consistent with FXS including macroorchidism. Metformin was initiated to treat his obesity and behavior at 500 mg qd, increasing to 500 mg bid after 1 week.
He had an excellent response to metformin over the subsequent 6 months. His appetite decreased and he lost 14 pounds over 6 months and he was very proud of this weight loss. He has better self-initiative and he will carry out chores such as cleaning his room or cleaning the house without excessive urging or reminders. He helps his mom with gardening and is able to coordinate the rake better. Regarding his language he talks much more on metformin. He has a lot of trivia knowledge such as why the titanic sank and now he is asking more inquisitive questions such as "where is Halifax?"
Mother is able to have a discussion with him even about emotional issues. He is able to talk about his grief and to relate his father's demise to his excessive smoking and drinking problems. He seems to be putting together concepts better and having back-and-forth conversations. His speech and language therapist has noted more language. He has not had any diarrhea nor loose stools with metformin.
He continues to have a nose rubbing tic which was problematic after the aripiprazole was discontinued (see Tables 1 and 2 ).
| Case 6-FXS/PWP
Case 6 was originally seen at age 10 years 4 months and his history included hypotonia in infancy with a poor suck after birth and oral motor coordination problems. Although he was thin in early childhood he developed a voracious appetite between 6 to 8 years of age and a lack of satiation after meals. He subsequently gained weight and was 222 lbs at age 15 although dieting helped to lower his weight somewhat. He had delayed puberty, at age 15.
On examination at age 16, his BP was 112/68, head circumference At age 24 he was started on metformin at 500 mg bid for his obesity and behavior difficulties. He had a dramatic improvement in his behavior on metformin and he has not had an outburst since he started treatment approximately 9 months ago. He also seems happier, more active and his family reports improvement in his language.
He is able to carry out a two way conversation and he became more outgoing socially with less anxiety. He has not experienced any change in appetite nor weight loss, he currently weighs 300 pounds, similar to baseline; however, he now eats without gorging himself.
The metformin dose was increased to 1000 mg bid to help him improve his weight loss after the initial 9 months of treatment.
| Case 7.-Child
This 4 year and 6-month-old boy with FXS was diagnosed at 14 months when FMR1 DNA testing was carried out because of motor delays. He was born after a normal pregnancy and his birth weight was 7 lbs 6 oz. He had problems latching to the breast and he was generally hypotonic. He had motor delays and began sitting independently at 10.5 months, and walking independently at 22 months.
His language was delayed and at a chronological age of 16 months his language age was 9 months for both expressive and receptive language on the Mullen. He had staring spells but his EEG did not show spike wave discharges. At 2 years, there was no language and his parents self-treated him with cannabinoid (CBD) tincture at approximately 40 mg qd and saw a decrease in staring spells. They felt that he began to verbalize more and his anxiety improved. They began low-dose sertraline at 2 years 3 months at 2 mg/day and subsequently 4 mg/day and his verbalizations improved with speaking in words. Minocycline was started at 25 mg/day before age 3 years and parents saw improvement and he was putting 2 words together by age 3 years 3 months. He was also receiving OT and Speech and Language therapy twice a week in addition to preschool and Early Start Denver Model in home at 9 hours a week.
At age 4 years 6 months his BP was 108/76, height was 97 cm (9%ile) and weight was 14.8 kg (47%ile). His physical features were typical for FXS including a broad forehead, prominent ears and an intermittent right exotropia, high palate, hyperextensible finger joints and flat feet.
After hearing about the KO mouse research at the National Fragile X Foundation (NFXF) conference the mother was interested in trying metformin for her son. After 6 months of a dose of 50 mg, the family felt he has fewer outbursts or tantrums, better attention, less hyperactivity and improvements in his language. Developmental testing after 4 months of treatment at 4.5 years showed expressive language at the 31 month age equivalent. There have been no noted side effects, and labs after 9 months of treatment are in Table 1 . His scores on the Aberrant Behavior Checklist (ABC) are seen in Table 2 .
| DISCUSSION
Metformin has not been previously used specifically for treatment of FXS. 9 However, the recent reports of improvement in the phenotype of FXS in animal models 19, 21 have generated new attention to metformin and the conditions that it treats including obesity and type 2 diabetes. Diabetes is very rare in FXS presumably because of upregulation of the insulin receptor as documented in the Drosophila model of FXS. 19 Here we describe a rare case of type 2 diabetes in Case 1 who improved significantly in his metabolic parameters including lowering of his elevated HgbA1c in addition to improvement in his fasting glucose with metformin treatment. Most importantly, however, he has improvement in his behavior and language suggesting a cognitive benefit from metformin. Other cases described here include those with obesity with and without the PWP and metformin is indicated clinically in such cases. The PWP of FXS is not uncommon and these patients can benefit from metformin because of their significant obesity and eating behavior which can improve on metformin as is seen in Cases 2 and 3. Those with significant obesity even without the PWP can also benefit from metformin even at an older age as demonstrated in Case 4.
An important element in all of these cases is a general improvement in behavior as documented in the ABC seen in Table 2 Although metformin is an obvious treatment for those patients with FXS with obesity, the PWP of FXS and those with type 2 diabetes, the patients reported here suggest that there may also be benefits to language, cognition and, behavior problems such as overeating, irritability, social avoidance and aggression. Because of the dual effects on metabolism in those with obesity in addition to the cognitive and behavioral effects, we recommend a controlled trial of metformin in children and adults with FXS to better understand the safety and efficacy in both behavior and cognition.
